9.295
price down icon5.15%   -0.505
after-market Handel nachbörslich: 9.15 -0.145 -1.56%
loading
Schlusskurs vom Vortag:
$9.80
Offen:
$9.68
24-Stunden-Volumen:
290.19K
Relative Volume:
0.07
Marktkapitalisierung:
$84.24M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.42M
KGV:
-1.6594
EPS:
-5.6013
Netto-Cashflow:
$-7.45M
1W Leistung:
-3.98%
1M Leistung:
-34.95%
6M Leistung:
-29.48%
1J Leistung:
-61.27%
1-Tages-Spanne:
Value
$9.08
$9.75
1-Wochen-Bereich:
Value
$9.03
$10.89
52-Wochen-Spanne:
Value
$1.80
$25.69

Cervomed Inc Stock (CRVO) Company Profile

Name
Firmenname
Cervomed Inc
Name
Telefon
(617) 744-4400
Name
Adresse
20 PARK PLAZA, BOSTON
Name
Mitarbeiter
15
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
CRVO's Discussions on Twitter

Vergleichen Sie CRVO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CRVO
Cervomed Inc
9.295 84.24M 0 -6.42M -7.45M -5.6013
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Cervomed Inc Stock (CRVO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-13 Hochstufung Chardan Capital Markets Neutral → Buy
2024-12-17 Herabstufung H.C. Wainwright Buy → Neutral
2024-12-11 Herabstufung Chardan Capital Markets Buy → Neutral
2024-12-11 Herabstufung Morgan Stanley Overweight → Underweight
2024-12-10 Herabstufung D. Boral Capital Buy → Hold
2024-12-06 Eingeleitet ROTH MKM Buy
2024-12-05 Eingeleitet H.C. Wainwright Buy
2024-09-18 Eingeleitet Chardan Capital Markets Buy
2024-07-26 Eingeleitet Morgan Stanley Overweight
2024-02-15 Eingeleitet Canaccord Genuity Buy
2020-11-17 Herabstufung H.C. Wainwright Buy → Neutral
2018-03-21 Eingeleitet H.C. Wainwright Buy
Alle ansehen

Cervomed Inc Aktie (CRVO) Neueste Nachrichten

pulisher
Apr 19, 2025

What Will CervoMed Inc (NASDAQ: CRVO) Be Like In 2025 - Stocksregister

Apr 19, 2025
pulisher
Apr 18, 2025

CervoMed Inc. Announces Executive Appointments and Officer Departure By Investing.com - Investing.com South Africa

Apr 18, 2025
pulisher
Apr 18, 2025

CervoMed Announces Executive Appointments and Changes - MSN

Apr 18, 2025
pulisher
Apr 18, 2025

CervoMed Inc. Announces Executive Appointments and Officer Departure - Investing.com Australia

Apr 18, 2025
pulisher
Apr 15, 2025

CervoMed (CRVO) to Present Key Findings on Dementia Drug at Inte - GuruFocus

Apr 15, 2025
pulisher
Apr 14, 2025

CervoMed (CRVO) Reports Positive Phase 2b Results for Neflamapim - GuruFocus

Apr 14, 2025
pulisher
Apr 07, 2025

CervoMed Reports Positive Phase 2b Trial Results - TipRanks

Apr 07, 2025
pulisher
Apr 04, 2025

Brokerages Set CervoMed Inc. (NASDAQ:CRVO) Price Target at $27.50 - Defense World

Apr 04, 2025
pulisher
Apr 02, 2025

CervoMed To Present Phase 2b Data On Neflamapimod's Impact On DLB At AD/PD 2025 - Nasdaq

Apr 02, 2025
pulisher
Apr 02, 2025

CervoMed to present results on Phase 2b RewinD-LB study - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025 - GlobeNewswire

Apr 02, 2025
pulisher
Apr 02, 2025

CervoMed Inc. to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD 2025 - marketscreener.com

Apr 02, 2025
pulisher
Apr 02, 2025

Virtu Financial LLC Invests $26,000 in CervoMed Inc. (NASDAQ:CRVO) - Defense World

Apr 02, 2025
pulisher
Mar 31, 2025

Biotech Stocks Q1 2025 Recap: Winners And Underperformers - Seeking Alpha

Mar 31, 2025
pulisher
Mar 28, 2025

CervoMed (CRVO) Projected to Post Quarterly Earnings on Friday - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

FY2025 EPS Estimates for CervoMed Lowered by Chardan Capital - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

CervoMed (NASDAQ:CRVO) Given Buy Rating at D. Boral Capital - Defense World

Mar 27, 2025
pulisher
Mar 27, 2025

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Mar 27, 2025
pulisher
Mar 26, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Mar 26, 2025
pulisher
Mar 25, 2025

CervoMed Announces Oral Presentation at 19th International - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

CervoMed Inc. to Present Findings on Neflamapimod in Dementia with Lewy Bodies at AP/PD™ Conference 2025 - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™) - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™) - TradingView

Mar 25, 2025
pulisher
Mar 25, 2025

New Clinical Data: CervoMed's Breakthrough Dementia Drug Results Revealed at Global Conference - Stock Titan

Mar 25, 2025
pulisher
Mar 24, 2025

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Mar 24, 2025
pulisher
Mar 22, 2025

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats - Seeking Alpha

Mar 22, 2025
pulisher
Mar 22, 2025

CervoMed Stock: Extension Study Data In Dementia Is Potentially Exciting, With Caveats - Seeking Alpha

Mar 22, 2025
pulisher
Mar 21, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Mar 21, 2025
pulisher
Mar 21, 2025

Roth Capital Issues Negative Forecast for CervoMed Earnings - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Brokers Offer Predictions for CervoMed Q1 Earnings - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Q1 Earnings Forecast for CervoMed Issued By Roth Capital - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts? - Insider Monkey

Mar 19, 2025
pulisher
Mar 19, 2025

CervoMed reports FY24 EPS ($2.02), consensus ($1.85) - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

CervoMed Inc (CRVO) Reports Q4 Net Loss of $16.3 Million, Grant Revenue at $9.7 Million - GuruFocus.com

Mar 19, 2025
pulisher
Mar 19, 2025

Roth Mkm Issues Positive Forecast for CervoMed (NASDAQ:CRVO) Stock Price - Defense World

Mar 19, 2025
pulisher
Mar 19, 2025

CervoMed (NASDAQ:CRVO) Given New $21.00 Price Target at Canaccord Genuity Group - Defense World

Mar 19, 2025
pulisher
Mar 19, 2025

Best Biotech Stocks To Watch Now – March 17th - Defense World

Mar 19, 2025
pulisher
Mar 19, 2025

10 Best Short Squeeze Stocks To Buy According to Analysts - Insider Monkey

Mar 19, 2025
pulisher
Mar 18, 2025

CervoMed price target raised to $20 from $15 at Roth MKM - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Following A Monumental March, Can CRVO Keep The Rally Going In April? - RTTNews

Mar 18, 2025
pulisher
Mar 18, 2025

CervoMed sees cash runway into mid-2026 - MSN

Mar 18, 2025
pulisher
Mar 18, 2025

CervoMed Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St

Mar 18, 2025
pulisher
Mar 18, 2025

CervoMed price target raised to $21 from $12 at Canaccord - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

CervoMed Inc. (CRVO): The Best Short-Term Stock to Buy Right Now - Insider Monkey

Mar 18, 2025
pulisher
Mar 18, 2025

Cervomed Inc. Faces Financial Hurdles Due to Regulatory Restrictions on Public Float - TipRanks

Mar 18, 2025
pulisher
Mar 17, 2025

Small Cap Stocks To Watch NowMarch 13th - MarketBeat

Mar 17, 2025
pulisher
Mar 17, 2025

Peering Into CervoMed's Recent Short Interest - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - MarketScreener

Mar 17, 2025
pulisher
Mar 17, 2025

CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

CervoMed's Breakthrough in Lewy Body Dementia Treatment Shows Promise in Latest Financial Report - StockTitan

Mar 17, 2025
pulisher
Mar 17, 2025

Why CervoMed Inc. (CRVO) Soared Last Week? - Insider Monkey

Mar 17, 2025

Finanzdaten der Cervomed Inc-Aktie (CRVO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Kapitalisierung:     |  Volumen (24h):